Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype

Journal of Alzheimer's Disease

Volumn 52, Issue 1, 2016, Pages 359-371

  Tramutola, Antonella ^a   Pupo, Gilda ^a   Di Domenico, Fabio ^a   Barone, Eugenio ^a,b   Arena, Andrea ^a   Lanzillotta, Chiara ^a   Broekaart, Diede ^c   Blarzino, Carla ^a   Head, Elizabeth ^d   Butterfield, D Allan ^d,e   Perluigi, Marzia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; caspase; p53; sirtuins; trisomy 21; Ts65Dn mouse model

Indexed keywords

CASPASE 3; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SIRTUIN 1; SIRTUIN 2;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; UPREGULATION; ACETYLATION; ANIMAL; C3H MOUSE; C57BL MOUSE; DISEASE MODEL; FRONTAL LOBE; IMMUNOPRECIPITATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE; WESTERN BLOTTING; YOUNG ADULT;

ACETYLATION; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; FRONTAL LOBE; HUMANS; IMMUNOPRECIPITATION; MALE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; PHENOTYPE; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84973143959     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-151105     Document Type: Article

References (68)

1. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH (2002) The changing survival profile of people with Down's syndrome: Implications for genetic counselling. Clin Genet 62, 390-393
2. Rueda N, Florez J, Martinez-Cue C (2013) Apoptosis in Down's syndrome: Lessons from studies of human and mouse models. Apoptosis 18, 121-134
3. Golden JA, Hyman BT (1994) Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol 53, 513-520
4. Guidi S, Bonasoni P, Ceccarelli C, Santini D, Gualtieri F, Ciani E, Bartesaghi R (2008) Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 18, 180-197
5. Contestabile A, Fila T, Ceccarelli C, Bonasoni P, Bonapace L, Santini D, Bartesaghi R, Ciani E (2007) Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 17, 665-678
6. Contestabile A, Fila T, Cappellini A, Bartesaghi R, Ciani E (2009) Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. Cell Prolif 42, 171-181
7. Rueda N, Mostany R, Pazos A, Florez J, Martinez-Cue C (2005) Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci Lett 380, 197-201
8. Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun 331, 761-777
9. Checler F, Alves Costa C (2014) p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther 142, 99-113
10. Bieging KT, Mello SS, Attardi LD (2014) Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14, 359-370
11. Rufini A, Tucci P, Celardo I, Melino G (2013) Senescence and aging: The critical roles of p53. Oncogene 32, 5129-5143
12. Fiorini A, Sultana R, Barone E, Cenini G, Perluigi M, Mancuso C, Cai J, Klein JB, St Clair D, Butterfield DA (2012) Lack of p53 affects the expression of several brain mitochondrial proteins: Insights from proteomics into important pathways regulated by p53. PLoS One 7, e49846
13. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21, 307-315
14. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1, 1001-1008
15. Liu B, ChenY, ClairDK(2008) ROS and p53:Aversatile partnership. Free Radic Biol Med 44, 1529-1535
16. Brooks CL, Gu W (2011) The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2, 456-462
17. Nakamura S, Roth JA, Mukhopadhyay T (2000) Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 20, 9391-9398
18. Gu W, Roeder RG (1997) Activation of p53 sequencespecific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606
19. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W (2004) Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A 101, 2259-2264
20. Cardaci S, Filomeni G, Rotilio G, Ciriolo MR (2008) Reactive oxygen species mediate p53 activation and apoptosis induced by sodium nitroprusside in SH-SY5Y cells. Mol Pharmacol 74, 1234-1245
21. Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J, Eriksson S, Hedstrom E, Issaeva N, Kel A, Arner ES, Selivanova G (2014) ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 21, 612-623
22. Di Domenico F, Pupo G, Tramutola A, Giorgi A, Schinina ME, Coccia R, Head E, Butterfield DA, Perluigi M (2014) Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: Clues for understanding the development of Alzheimer disease. Free Radic Biol Med 71, 270-280
23. Perluigi M, Di Domenico F, Buttterfield DA (2014) Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: Insights from proteomics. Proteomics Clin Appl 8, 73-85
24. Butterfield DA, Domenico F, Swomley AM, Head E, Perluigi M (2014) Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J 463, 177-189
25. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H, Lott IT, Schmitt FA, Butterfield DA, Head E (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822, 130-138
26. Di Domenico F, Coccia R, Cocciolo A, Murphy MP, Cenini G, Head E, Butterfield DA, Giorgi A, Schinina ME, Mancuso C, Cini C, Perluigi M (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain. Biochim Biophys Acta 1832, 1249-1259
27. Perluigi M, Pupo G, Tramutola A, Cini C, Coccia R, Barone E, Head E, Butterfield DA, Domenico F (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta 1842, 1144-1153
28. Reinholdt LG, Ding Y, Gilbert GJ, Czechanski A, Solzak JP, Roper RJ, Johnson MT, Donahue LR, Lutz C, Davisson MT (2011) Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome 22, 685-691
29. Silva AR, Santos AC, Farfel JM, Grinberg LT, Ferretti RE, Campos AH, Cunha IW, Begnami MD, Rocha RM, Carraro DM, Braganca Pereira CA, Jacob-Filho W, Brentani H (2014) Repair of oxidative DNA damage, cellcycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease. PLoS One 9, e99897
30. Brooks CL, GuW(2010) New insights into p53 activation. Cell Res 20, 614-621
31. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137, 609-622
32. van Leeuwen I, Lain S (2009) Sirtuins and p53. Adv Cancer Res 102, 171-195
33. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11, 437-444
34. Hoffmann G, Breitenbucher F, Schuler M, Ehrenhofer-Murray AE (2014) A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem 289, 5208-5216
35. Lanni C, Uberti D, Racchi M, Govoni S, Memo M (2007) Unfolded p53: A potential biomarker for Alzheimer's disease. J Alzheimers Dis 12, 93-99
36. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM (2014) Senescence and apoptosis: Dueling or complementary cell fates? EMBO Rep 15, 1139-1153
37. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti GM (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 66, 352-361
38. Sheng B,Wang X, Su B, Lee HG, Casadesus G, Perry G, Zhu X (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 120, 419-429
39. Lott IT, Head E (2001) Down syndrome and Alzheimer's disease: A link between development and aging. Ment Retard Dev Disabil Res Rev 7, 172-178
40. Busciglio J, Yankner BA (1995) Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378, 776-779
41. Friedlander RM (2003) Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348, 1365-1375
42. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H (1999) Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 155, 1459-1466
43. Esposito E, Cuzzocrea S (2010) New therapeutic strategy for Parkinson's and Alzheimer's disease. Curr Med Chem 17, 2764-2774
44. Cenini G, Sultana R, Memo M, Butterfield DA (2008) Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J Cell Mol Med 12, 987-994
45. Di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M, Butterfield DA (2009) Glutathionylation of the pro-apoptotic protein p53 in Alzheimer's disease brain: Implications for AD pathogenesis. Neurochem Res 34, 727-733
46. Cenini G, Sultana R, Memo M, Butterfield DA (2008) Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic Biol Med 45, 81-85
47. MonteSM(1999) Molecular abnormalities of the brain in Down syndrome: Relevance to Alzheimer's neurodegeneration. J Neural Transm Suppl 57, 1-19
48. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL (2001) Acetylation of p53 activates transcription through recruitment of coactivators/ histone acetyltransferases. Mol Cell 8, 1243-1254
49. Liu G, Chen X (2006) Regulation of the p53 transcriptional activity. J Cell Biochem 97, 448-458
50. Wang DB, Kinoshita C, Kinoshita Y, Morrison RS (2014) p53 and mitochondrial function in neurons. Biochim Biophys Acta 1842, 1186-1197
51. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279, 53015-53022
52. Donmez G, Outeiro TF (2013) SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Mol Med 5, 344-352
53. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-966
54. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107, 137-148
55. Coppe JP, Patil CK, Rodier F, Krtolica A, Beausejour CM, Parrinello S, Hodgson JG, Chin K, Desprez PY, Campisi J (2010) A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One 5, e9188
56. Helguera P, Pelsman A, Pigino G, Wolvetang E, Head E, Busciglio J (2005) ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci 25, 2295-2303
57. Seidl R, Cairns N, Lubec G (2001) The brain in Down syndrome. J Neural Transm Suppl, 247-261
58. Salemi M, Barone C, Romano C, Ridolfo F, Gulotta E, Scavuzzo C, Salluzzo MG, Giambirtone M, Caraci F, Romano C, Bosco P (2011) Differential expression of PARP1 mRNA in leucocytes of patients with Down's syndrome. J Genet 90, 469-472
59. Anderson AJ, Stoltzner S, Lai F, Su J, Nixon RA (2000) Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. Neurobiol Aging 21, 511-524
60. Sun X, Wu Y, Chen B, Zhang Z, Zhou W, Tong Y, Yuan J, Xia K, Gronemeyer H, Flavell RA, SongW(2011) Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation. J Biol Chem 286, 9049-9062
61. Austin S, St-Pierre J (2012) PGC1alpha and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125, 4963-4971
62. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27, 728-735
63. Perluigi M, Butterfield DA (2012) Oxidative stress and Down syndrome: A route toward alzheimer-like dementia. Curr Gerontol Geriatr Res 2012, 724904
64. Lott IT, Head E, Doran E, Busciglio J (2006) Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 3, 521-528
65. Di Domenico F, Pupo G, Mancuso C, Barone E, Paolini F, Arena A, Blarzino C, Schmitt FA, Head E, Butterfield DA, PerluigiM(2015) Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-A system: Insights for transition to Alzheimer's disease. J Alzheimers Dis 44, 1107-1120
66. Guedj F, Pennings JL, Ferres MA, Graham LC, Wick HC, Miczek KA, Slonim DK, Bianchi DW (2015) The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome. Am J Med Genet A 167, 1993-2008
67. Guedj F, Pennings JL,Wick HC, BianchiDW(2015) Analysis of adult cerebral cortex and hippocampus transcriptomes reveals unique molecular changes in the Ts1Cje mouse model of down syndrome. Brain Pathol 25, 11-23
68. Olsson A, Manzl C, Strasser A, Villunger A (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14, 1561-1575